Business Context and Reporting Period
ImmuCell Corporation (ICCC) filed a Form 8-K on January 8, 2026, reporting preliminary, unaudited sales results for the three-month and twelve-month periods ended December 31, 2025. The company is shifting its strategic focus from the Re-Tain product line to its lead product, First Defense.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin figures, noting only that preliminary sales results were announced in a press release (Exhibit 99.1). The document details significant non-cash impairment charges totaling approximately $3.6 million for the quarter ended December 31, 2025.
- Total Impairment Charges: Approximately $3.6 million (non-cash).
- Re-Tain Asset Write-down: Approximately $2.9 million related to property, plant, and equipment.
- Other Asset Write-downs: $0.1 million for property, plant, and equipment.
- Inventory Write-down: $0.6 million for work-in-process colostrum inventory deemed unfit for processing.
- Re-Tain Net Book Value (as of Sept 30, 2025): Approximately $15.5 million.
The filing states these charges are not expected to result in material future cash expenditures. Specific debt and liquidity metrics are not disclosed in this text.
Material Changes
The primary material change is the decision to pause further investment in the Re-Tain product line following an FDA Incomplete Letter. This decision was triggered by the company's contract manufacturer failing to satisfactorily address previously cited inspectional deficiencies. Consequently, the company is repurposing most Re-Tain assets for the expanded production of First Defense.
Outlook, Risks, and Unusual Items
Strategic Shift: Management is pivoting away from Re-Tain to focus on First Defense. The company expects to repurpose Re-Tain assets for First Defense production.
Risks and Contingencies: The actual timing, fair values, and related impairment charges may differ materially from current estimates due to the inherent nature of the estimates. The FDA Incomplete Letter regarding the contract manufacturer represents a significant operational risk that has already impacted the Re-Tain project.
Unusual Items: The $3.6 million in impairment charges are non-cash items resulting from the strategic pause and inventory obsolescence.
Investor Verification Checklist
- Verify the specific preliminary sales figures for Q4 and full-year 2025 in the press release (Exhibit 99.1) referenced in this filing.
- Confirm the status of the FDA inspectional deficiencies at the contract manufacturer and the timeline for resolution.
- Review the full unaudited financial results scheduled for release after market close on February 25, 2026.
- Assess the feasibility and timeline for repurposing Re-Tain assets for First Defense production.
- Monitor the company's cash position given the strategic shift and potential delays in revenue from the paused Re-Tain line.